191 results
Page 2 of 10
8-K
EX-99.1
m6ucyrtxxfd0uqyi
6 Jan 22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
5:18pm
8-K
EX-99
3nisid
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
EX-99.1
07aggjyi 0ux9p5v
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
8-K
EX-99.1
bhwpgm7cwbxahi2w41h
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am
8-K
EX-99.1
vl1t lxe6h9nclgw49f9
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
EX-99.2
xz05e0aevff0 l837947
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
EX-99.1
qhdyuns vd
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
EX-99.1
8mmt8
29 Sep 21
Other Events
9:22am
8-K
EX-99.1
0kh7l8
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
EX-99.1
n1f36qjsgo qe
26 Jul 21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
12:00am
8-K
EX-99.1
t3nprtt4
13 Jul 21
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
10:38am
DEFA14A
EX-99.1
j3c02 p9uzl4
25 Jun 21
Additional proxy soliciting materials
4:48pm
8-K
EX-99.1
igfgqwktrprsgv0g9rww
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm
8-K
EX-99.1
haaj6n 9lsu
9 Jun 21
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
9:06am